May 7, 2026
Anagram Therapeutics
Anagram Therapeutics develops orally delivered enzyme therapies for malabsorption syndromes and nutrient deficiencies.
- Round
- Private Equity
- Amount raised
- $250M
- Lead investor
- Blackstone Life Sciences
- Industry
- Biotechnology
- Headquarters
- Boston, United States
- Employees
- 11-50
- Website
- anagramtx.com
- View profile →
Other investors
- Cystic Fibrosis Foundation
Source: Crunchbase snapshot 2026-05-15